Financials

  • Market Capitalization 344.9 M
  • Employee 50
  • Founded 2019
  • CEO N/A
  • Website www.helus.com
  • Headquarter Ontario, Canada
  • FIGI BBG00MFNRRT4
  • Industry Biotechnology
Total revenue
Net income
Total debt
Free cash flow
Cash & equivalents

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
3206
PRLD
Prelude Therapeutics Incorporated - Common Stock
4.39 USD-1.13%-11.49%+0.46%+441.98%349.64 M USD
3210
FATE
Fate Therapeutics, Inc. - Common Stock
2.99 USD-0.99%+2.40%+47.29%+162.28%348.51 M USD
3225
ZNTL
Zentalis Pharmaceuticals, Inc. - common stock
4.77 USD+3.25%0.00%+26.86%+253.33%339.56 M USD
3229
IMRX
Immuneering Corporation - Class A Common Stock
5.21 USD+0.97%+0.97%+24.34%+28.33%337.07 M USD

Frequently asked questions about Cybin Inc. - Common Stock

What is the Cybin Inc. - Common Stock stock price today?

The current price of Cybin Inc. - Common Stock (HELP) is 6.68. Over the past 24 hours, the stock has changed by -0.30%. Follow the HELP chart for real-time price dynamics.

What is the stock ticker of Cybin Inc. - Common Stock?

Cybin Inc. - Common Stock trades under the ticker HELP. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Cybin Inc. - Common Stock stock going up?

HELP has changed by +13.03% over the last week, +56.81% over the last month, and -25.53% over the last year. Review the chart to see whether the current move is part of a broader trend.

How many employees does Cybin Inc. - Common Stock have?

As of the latest available data, Cybin Inc. - Common Stock has 50 employees. Workforce size can provide additional context about the company's scale and operations.

How can I buy Cybin Inc. - Common Stock stock?

You can buy Cybin Inc. - Common Stock (HELP) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Cybin Inc. - Common Stock stock?

Investing in Cybin Inc. - Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the HELP chart and related analysis on metatrader.com as part of your research.

Cybin Inc. - Common Stock

Helus Pharma, also known formerly as Cybin IRL, is a Canadian pharmaceutical company that was led by CEO Doug Drysdale from 2020-2025, developing psychedelic drugs as medicines. The company's drug candidates include psilocybin, HLP002, HLP003, HLP004, HLP005, and HLP006. Another drug that the company has developed is CYB210010. As of January 2025, HLP003 is in phase 3 clinical trials. The drug is one of the only other psychedelics besides Compass Pathways's COMP360 to have reached this late stage of clinical development. In 2020, Helus Pharma acquired psychedelic pharmaceutical company Adelia Therapeutics. In late 2023, it acquired Small Pharma, the developer of SPL026 and SPL028. Helus Pharma was originally known as Cybin but changed its name in December 2025.